|
You are here:
Manager factsheet
|
|
Manager profile
Tim Freeborn is an equities analyst and joined Slater Investments in February 2017. Since qualifying as a Chartered Accountant, Tim has had a varied career. For many years he was a City writer at The Daily Mail, he has also edited an investment newsletter and contributed to Shares Magazine. This was followed by several years as a stockbroking analyst at Evolution Securities and Xcap Securities covering growth companies. Before joining Slater Investments, Tim spent four years as the Chief Financial Officer of Silence Therapeutics, an Aim listed biotech company, and latterly ran its laboratories in Berlin. Tim serves on the Investment Committee.
|
|
|
 | |  |
|
|
|
 |
Annualised total return over 6.3 years |
+2.7% |
 |
|
| |
1 year |
3 years |
5 years |
7 years |
10 years |
| Tim Freeborn |
15.6 |
8.4 |
24.1 |
- |
- |
Peer Group Composite
|
17.2 |
15.4 |
26.5 |
- |
- |
| Over / Under |
-1.6 |
-7.0 |
-2.4 |
- |
- |
|
|
|
 |
|
 |
|
|
|
Total return for Tim Freeborn
|
|
|
Discrete calendar year performance : Tim Freeborn
Funds managed previously
| Fund |
Periods |
|
| No previously managed funds |
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.
You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser. Close